There has been considerable interest in p53 mutation in lowgrade B-cell malignancies over the years, particularly in chronic lymphocytic leukaemia (CLL). CLL exhibits a highly variable clinical course; p53 mutation confers a worse prognosis and adversely affects response to purine analogue therapy. Reported rates of mutation of the p53 gene in B-cell malignancies vary between studies and subtypes, but are not common. 1 The majority of studies have restricted mutation screening to exons 5-8, so the true rate of mutation outside of this region is not known.
The non-isotopic RNase cleavage assay (NIRCA) works on the principle that RNase cleaves both strands of duplex RNA targets at mismatched bases and has been previously developed and validated as a method for screening for the presence of mutated p53 mRNA. 2 Briefly single stranded RNA is synthesized from opposing strands of patient PCR product and wild type control product, of the entire p53 coding region (from viral promoter sequences incorporated during PCR) and opposing RNA strands are hybridized. Subsequent digestion with RNase and analysis by agarose gel electrophoresis and ethidium bromide staining results in the observation of digested product for those samples containing a mismatch between patient and wild type sequence. We have used NIRCA to screen the entire coding region of the p53 gene from 480 patients diagnosed with a low-grade B-cell malignancy for p53 mutations (see Table 1 for disease classification).
The population of patients seen at our centre are very different from those seen at referral centres (where the majority of studies are carried out) and could be considered a more genuine representation of an unselected CLL population. In our patient population, 62.5% have never required treatment, 83% have stage A disease and many never require a follow up appointment. Our p53 mutation rate of 4% in CLL, although lower than many early studies, is in line with the only other study that we are aware of on a similar population of patients by Oscier et al.
(when patients specifically selected for inclusion due to known p53 mutation are excluded, an overall p53 mutation rate of 4% was found). 4 Many early studies did not benefit from the improved classification of patients that is now possible due to flow cytometric, cytogenetic and molecular biological techniques, resulting in inclusion of pathologies such as mantle cell lymphoma in leukaemic phase with CLL. When strict classification is applied the rate of cytogenetic abnormalities in CLL appears reduced. 3 Most studies report the rate of p53 abnormalities as a combination of deletion and mutation, the mutation rate alone is therefore lower than the 10-15% often quoted.
A total of 24 patients were found to have a p53 mutation and 23 of these mutations were in the DNA binding domain of the p53 gene (exons 5-8), suggesting that restricting screening to exons 5-8 in low-grade B-cell malignancies will not exclude detection of a large number of mutations. The aberrant mRNA present in the remaining patient (Patient 1) was missing exon 4 entirelyFthis could have arisen due to a splice site mutation, such mutations have been previously reported in CLL.
5 Studies over the years have reached different conclusions as to the distribution of p53 mutations in B-cell malignancies, few have screened the complete coding region of the gene. However Cordone et al.
6 reported 4/14 mutations to be outside of the evolutionary conserved region in direct contrast to our findings.
Trbusek et al. 7 recently published a study using a functional yeast assay in which they found 15/168 CLL patients to be p53 mutated; surprisingly, all of the mutations were different and only one affected a mutation hotspot codon for p53 mutation (codon 248). However, only 3/15 of their reported mutations did not affect codons with over 100 reported mutations on the UMD p53 mutation database.
8 In our present cohort of patients (Table 2) , 7/24 mutations affected the classic 'hotspot' codons 175, 248 and 273 with only 6 mutations that did not affect a commonly mutated codon.
8 Most studies report a similar distribution of p53 mutation in haematological malignancy. Two patients exhibited identical mutations at codon 248 which resulted in substitution of arginine by glycine rather than the commonly reported substitution by tryptophan or glutamine. There are reports of this mutation in the UMD p53 database in solid tumours (12 cases), Burkitts lymphoma (1 case), Diffuse Large B-cell lymphoma (1 case) and CLL (1 case) who is included in this study and in a previous report by this laboratory.
8 Although rare, this particular substitution results in almost complete abolition of p53 activity in common with the other recurrent mutations of this codon. 8 The mutation at codon 273 seen in two patients resulted in the frequently found arginine to histidine substitution. The mutation profile was in line with that seen overall for mutations in the exon 5-8 region of the gene, with 18/23 (78%) causing amino acid substitution, 1/23 (4%) nonsense and 3/23 (13%) were in frame deletions. The remaining patient with an abnormality had a complex mutation, which resulted in both deletion of eight amino acids and also substitution of a single amino acid with the remainder of the transcript in frame. Outside of exons 5-8 a higher percentage of frameshift and nonsense mutations are reported. Of the point mutations observed 9 were transitions and 9 transversions. Use of the UMD p53 database to assess the likely impact of the mutations observed in this current study on the transcriptional activity of p53 revealed that only the patient with a mutation at codon 203 retained any significant p53 transcriptional activity, although at a level below 50% that of wild type p53 (Table 2) . A recent in vitro study by Secchiero et al.
9 found that nutlin-3, a small molecule inhibitor of the p53/MDM2 interaction showed activity in CLL. Only one CLL sample studied was resistant, this patient was believed to have a p53 mutation. The fact that all p53 mutations in our current study resulted in severely compromised p53 transcriptional activity suggests that some evolving treatments may not provide any new advantage for patients like these. Out of 23 patients 15 also had deletion of one p53 allele by fluorescence in situ hybridization (FISH) analysis.
p53 mutations can be acquired during the course of the disease and therefore their absence cannot be considered a true marker of good prognosis at diagnosis. A total of 53 patients had more than one sample analysed, 4 patients (Patients 3, 4, 11 and 17) acquired p53 mutation between screening of subsequent samples, 3 of whom received treatment between samples (Patients 4, 11 and 17) and 1 (Patient 4) was known to have a p53 deletion as early as four years before mutation was detected. It is impossible to say whether these mutations were present at a level below detection (20% of leukaemic cells) and merely selected for by treatment or whether treatment resulted in the development of a p53 mutation. No common treatment was received by these three patients and one had received multiple regimens between samples. In fact only four of the mutated p53 patients were tested at diagnosis and nine had received treatment prior to testing, therefore we cannot say whether these mutations were present at diagnosis in the majority of our patients. Survival analysis of patients such as these is fraught with problems, it is therefore difficult to allocate a specific effect to the presence of p53 mutation. Even in those patients in whom mutation is identified at diagnosis the mutation may have been present for an indeterminate time previously. Additionally, patients developing aggressive/chemoresistant disease are more likely to have samples sent for subsequent screening and therefore an acquired mutation is more likely to be detected. To reliably estimate the impact of p53 mutation on survival it would be necessary to conduct a study with prospective screening of the gene from diagnosis and at regular intervals thereafter whether treatment is contemplated or not. This type of observational study is more difficult to mount than one in which treatments are assessed.
In conclusion, although p53 mutation is relatively rare, the type and distribution of mutations in low-grade B-cell malignancy patients does not differ significantly from other forms of cancer.
8 Table 2 p53 mutation summary Expression of a single antibody specificity by normal B cells is essential for the normal functioning of the immune system. Naive B cells express germline, unmutated immunoglobulin genes, but B cells that have encountered an antigen and moved through a germinal centre have antibody genes that bear mutations. Specific antigen-antibody interaction can drive proliferation and potentially this is significant in driving the proliferation of B-cell malignancies including chronic lymphocytic leukaemia (CLL). There is a biased V H gene usage in malignant B-cell populations (particularly CLL 1,2 ), which supports the importance of antibody-specific processes in driving or maintaining this malignancy. About half of all CLL cases have unmutated immunoglobulin genes and this is associated with poor clinical outcome. One allele of V H 1-69 in CLL is overexpressed in unmutated cases of CLL 3 and the sequence of the CDR3 region, which is important in antigen binding, is identical in a surprisingly high proportion of patients 4, 5 again suggesting that antigen-driven processes may be important in leukaemogenesis. There is much less work on the light-chain V gene usage in CLL but there is a biased usage of both k and l light chains. 6 We have sequenced rearranged V L genes from l expressing cases of CLL. In distinction to the previous work on V l gene usage based on southern European 6 or North American populations, our cases are drawn from northern Europe.
We have PCR amplified (see figure legend) and sequenced rearranged V l gene segments from DNA extracted from B cells purified from peripheral blood. Eighty-one rearrangements were amplified from CLL and the PCR product was cloned and sequenced. Sequences were compared to those of germline V l genes compiled in the IMGT database 7 in order to find the most likely V l gene, J l gene and mutational status.
There was highly preferential usage of certain V l gene segments (Figure 1a ) in CLL. IGL3-21n01 was used in 37% of the cases and IGL2-14n01, IGL2-14n03, IGL3-21n02 and IGL10-54n01 all being used in more than 5% of the rearrangements. The overall usage of IGL3-21 (including both the IGL3-21n01 and IGL3-21n02 alleles) is 44%. Others 6 showed a similar high frequency of IGL3-21n01 at 21%, but did not find any cases expressing IGL3-21n02. However, we also found several V l gene segments (IGL1-41n01, IGL1-47n01, IGL2-14n03 and IGL5-45n03) that had not previously been reported in CLL. There is also over-representation of IGL10-54n01 (6% in this study and 1% in Stamatopoulos et al. 6 ) and underrepresentation of IGL2-8n01 (3 and 14% in Stamatopoulos et al. 6 ). J2n01 and J3n02 were the predominant J l gene segments used in those cases where an assignment could be made. Overall, 32 rearrangements (40%) showed 498% homology to germline sequence and 49 rearrangements (60%) had significant number of mutations. However, among IGL3-21 rearrangements there was a statistically significant excess of unmutated sequences (P ¼ 0.01, Fisher's exact test) compared to all the other V l gene rearrangements.
The CDR3 region can be diversified at both the V(D)J recombination stage, within the bone marrow, and by somatic hypermutation at the germinal centre stage of development. It is, thus, an important contributor to antigen binding specificity. Analysis of CDR3 regions in CLL has demonstrated that unrelated cases can share structural features 8 and has allowed grouping into subsets, some of which showed homology for only light chains . 6 We undertook an analysis of CDR3 regions in our cases ( Figure 1b) . As others have reported, there is a striking similarity between IGL3-21 CDR3 regions in both length (12 amino acids) and sequence. This appears most prominent with
